For many years researchers have been trying to identify so-called “surrogate” endpoints that can be used to predict overall and prostate cancer-specific survival with high accuracy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: endpoint, outcome, predictive, surrogate, survival, trial | 1 Comment »
In a recent commentary, we looked at the utility of surrogate endpoints in evaluating therapies. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: association, endpoint, risk, surrogate, survival | 20 Comments »
It appears that when it comes to the new data to be presented at ASCO this year, this will be the first time for several years that we don’t see some really groundbreaking new data from a large Phase III trial of some new form of therapy at one of the major meetings. But there is a lot of detail and a lot of information about new trials in development. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: endpoint, hypothesis, surrogate, validation | Leave a comment »
Back in 2011 we reported a presentation by Scher et al. indicating that circulating tumor cell counts (CTCs) could probably be used to monitor responses to abiraterone acetate (and perhaps other forms of drug therapy) in the treatment of men with metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, activity, cell, circulating, count, CTC, surrogate, tumor | 3 Comments »
One of the problems with clinical trials for late-stage prostate cancer today is that we commonly need to follow all patients until death before we can collect sufficiently accurate data to be certain that a particular product is or is not effective in extending patient survival. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bone, BSI, endpoint, index, marker, scan, surrogate, survival | Leave a comment »
A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, cancer-specific, marker, mortality, neoadjuvant, progression, PSA, radiation, surrogate | 2 Comments »
Today’s news reports cover items on:
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, androgen deprivation, biopsy, cardiovasular, castration-resistant prostate cancer, complete, CRPC, hormone therapy, intermittent, marker, protocol, side effects, surrogate | Leave a comment »
Because it takes so long for men with even advanced prostate cancer to progress through to death from any cause, there has been extensive effort over the years to define “surrogate” endpoints for prostate cancer-specific and overall survival in prostate cancer clinical trials. … READ MORE …
Filed under: Drugs in development | Tagged: enpoint, overall, PSA progression, surrogate, survival | Leave a comment »
There have been several attempts to clearly define surrogate endpoints for prostate cancer-specific survival that could be used to shorten the length of clinical trials investigating the merits of specific forms of treatment for prostate cancer. A new analysis of data from the 1,554-patient RTOG 92-02 trial has further explored two such possibilities. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: endpoint, surrogate, survival | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 